NGM Bio’s NGM621 Receives Fast Track Designation from the FDA fo Long

Description

⋅ Feb 8, 2022 12:58 AM

NGM: NGM Biopharmaceuticals, Inc.
2022-02-07 08:00:00
NGM Bio’s NGM621 Receives Fast Track Designation from the FDA for the Treatment of Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration

Beyond Technical Analysis